Skip to main content
ORIC
NASDAQ Life Sciences

ORIC Initiates Phase 3 Trial for Prostate Cancer Drug, Secures Bayer Supply Deal

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$10.85
Mkt Cap
$1.092B
52W Low
$7.23
52W High
$14.93
52W Position info
50% above low
Off High info
27% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

ORIC sits 50% above its 52-week low of $7.23.

Summary

ORIC has started the Himalayas-1 global Phase 3 registrational trial for rinzimetostat in metastatic castration-resistant prostate cancer, a key step toward potential approval. The trial will enroll about 600 patients across 250 sites in 25 countries, with primary endpoint radiographic progression-free survival. Bayer will supply darolutamide at no cost under a clinical collaboration, while ORIC retains full rights to rinzimetostat. This follows positive Phase 1b data and FDA interactions, moving the lead asset into a pivotal study. The Bayer deal reduces trial costs and validates the combination approach. Topline data timing is not yet disclosed, but the trial's initiation marks a major derisking event for the pipeline.

At the time of this announcement, ORIC was trading at $10.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $7.23 to $14.93. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ORIC - Latest Insights

ORIC
Nov 16, 2026, 4:20 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.52
Real-time Price: $7.52 info
Change: $0 (0%) info
Market Cap: $779.468M info
ORIC
Nov 16, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.52
Real-time Price: $7.52 info
Change: $0 (0%) info
Market Cap: $779.468M info
ORIC
Nov 16, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.52
Real-time Price: $7.52 info
Change: $0 (0%) info
Market Cap: $779.468M info
ORIC
Oct 23, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.32
Real-time Price: $7.52 info
Change: -$5.80 (-44%) info
Market Cap: $779.468M info
ORIC
Oct 23, 2026, 3:15 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $13.85
Real-time Price: $7.52 info
Change: -$6.33 (-46%) info
Market Cap: $779.468M info